Johnathan J. Morris

Johnathan J. Morris

Auto-generated profile, based on publicly available information

Johnathan J. Morris

Raymond G. Perelman Center for Cellular and Molecular Therapeutics and Hematology, Children's Hospital of Philadelphia, Philadelphia, PA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2023 in Blood
Verified
Journal Article
Open access
PDF file
RKRadoslaw Kaczmarek
Radoslaw Kaczmarek
APAnnie R. Pineros
Annie R. Pineros
PPPaige E Patterson
Paige E Patterson
TBThais B. Bertolini
Thais B. Bertolini
GPGeorge Q. Perrin
George Q. Perrin
Roland W HerzogRoland W Herzog
Roland W Herzog
Despite over 80 years of clinical experience with coagulation factor (F)VIII inhibitors, surprisingly little is known about the in vivo mechanism of this most serious complication of replacement therapy for hemophilia A. These neutralizing anti-drug alloantibodies arise in ~30% of patients. Inhibitor formation is T cell-dependent, but events leading up to helper T cell activation have been elusive due in part to the complex anatomy and cellular makeup of the spleen. Here, we show that FVIII antigen presentation to CD4+ T cells critically depends on a select set of several anatomically distinct antigen presenting cells, whereby marginal zone B cells, marginal zone and marginal metallophilic but not red pulp macrophages (RPMFs) participate in shuttling FVIII to the white pulp where conventional dendritic cells (DCs) prime helper T cells, which then differentiate into follicular helper T (Tfh) cells. Toll-like receptor 9 (TLR9) stimulation accelerated Tfh responses, Germinal Center and inhibitor formation, while systemic administration of FVIII alone in hemophilia A mice increased frequencies of monocyte-derived and plasmacytoid DCs. Moreover, FVIII enhanced T cell proliferation to another protein antigen (ovalbumin), and inflammatory signaling-deficient mice were less likely to develop inhibitors, indicating that FVIII may have intrinsic immunostimulatory properties. Ovalbumin, which, unlike FVIII, is absorbed into the RPMF compartment, fails to elicit T cell proliferative and antibody responses when administered at the same dose as FVIII. Altogether, we propose that an antigen trafficking pattern that results in efficient in vivo delivery to DCs and inflammatory signaling, shape the immunogenicity of FVIII.

13 November 2021 in Toxicological Sciences
Verified
Journal Article
Open access
PDF file
JMJohnathan Morris
Johnathan Morris
EBElizabeth J Bealer
Elizabeth J Bealer
Ivan Domicio da Silva SouzaIvan Domicio da Silva Souza
Ivan Domicio da Silva Souza
LRLauren Repmann
Lauren Repmann
HBHannah Bonelli
Hannah Bonelli
MSMary M Staehle
Mary M Staehle
The growing number of commercially used chemicals that are under-evaluated for developmental neurotoxicity (DNT) combined with the difficulty in describing the etiology of exposure-related neurodevelopmental toxicity has created a reticent threat to human health. Current means of screening chemicals for DNT are limited to expensive, time-consuming, and labor-intensive traditional laboratory animal models. In this study, we hypothesize that exposed head-regenerating planarian flatworms can effectively and efficiently categorize DNT in known developmental neurotoxins (ethanol and bisphenol A [BPA]). Planarian flatworms are an established alternative animal model for neurodevelopmental studies and have remarkable regenerative abilities allowing neurodevelopment to be induced via head resection. Here, we observed changes in photophobic behavior and central nervous system (CNS) morphology to evaluate the impact of exposure to low concentrations of ethanol, BPA, and BPA industry alternatives bisphenol F, and bisguaiacol on neurodevelopment. Our studies show that exposure to 1% v/v ethanol during regeneration induces a recoverable 48-h delay in the development of proper CNS integrity, which aligns with behavioral assessments of cognitive ability. Exposure to BPA and its alternatives induced deviations to neurodevelopment in a range of severities, distinguished by suppressions, delays, or a combination of the 2. These results suggest that quick and inexpensive behavioral assessments are a viable surrogate for tedious and costly immunostaining studies, equipping more utility and resolution to the planarian model for neurodevelopmental toxicity in the future of mass chemical screening. These studies demonstrate that behavioral phenotypes observed following chemical exposure are classifiable and also temporally correlated to the anatomical development of the CNS in planaria. This will facilitate and accelerate toxicological screening assays with this alternative animal model.

30 October 2025 in Blood
Verified
Journal Article
Open access
JMJohnathan J. Morris
Johnathan J. Morris
NPNicole A. Parsons
Nicole A. Parsons
AWAmelia R. Wilhelm
Amelia R. Wilhelm
RDRobert J. Davidson
Robert J. Davidson
LOLauren K. Olenick
Lauren K. Olenick
LGLindsey A. George
Lindsey A. George
Deficiency of factor VIII (FVIII) causes hemophilia A (HA), and excess FVIII function increases venous thromboembolic risk. The phenotypic consequences of aberrant FVIII function underscore the importance of understanding mechanisms that downregulate activated FVIII (FVIIIa) to inform disease pathology and therapeutic drug design. Spontaneous A2-domain dissociation and activated protein C (APC) proteolysis are established mechanisms of FVIIIa inactivation. However, we know very little about how FVIIIa binding interactions with FIXa and FX affect FVIIIa inactivation in vivo. Here, we investigate this using recombinant FVIIIa variants to probe A2-domain dissociation (FVIIIa-D519V,E665V) and APC cleavage (FVIIIa-R336Q,R562Q), or both (FVIIIa-R336Q,R562Q/D519V,E665V), in biochemical assays and in HA mouse injury models. We found that FIXa binding to FVIIIa stabilized the A2 domain and increased the contribution of APC to FVIIIa inactivation. Additional studies using individual APC cleavage site variants (FVIIIa-R336Q and FVIIIa-R562Q) demonstrated that FIXa and FX can protect FVIIIa from APC cleavage at Arg562 and Arg336, respectively, in a manner that is incomplete in vivo. Data also demonstrate that APC inactivation of FVIIIa exceeds FVIII, suggesting differential APC recognition of FVIIIa relative to FVIII. Hemostatic studies of FVIII variants with altered inactivation demonstrated that both A2-domain dissociation and APC cleavage contribute to in vivo FVIIIa regulation. Specifically, stabilizing the A2 domain, inhibiting APC cleavage, or both, improved potency 2.4-, 4.8-, and >10-fold, respectively, over wild-type FVIII in a mouse hemostatic assay. Data support that both mechanisms of FVIIIa inactivation and FIXa interactions could be leveraged to enhance FVIII function for therapeutic benefit.

5 November 2026 in Blood
Verified
Journal Article
Open access
JMJohnathan J. Morris
Johnathan J. Morris
RDRobert J. Davidson
Robert J. Davidson
CWConnor T. Watson
Connor T. Watson
LGLindsey A. George
Lindsey A. George
Factor VIII Aurora (FVIII-R571S) is, to our knowledge, the first described naturally occurring enhanced-potency FVIII variant identified in a patient with recurrent thrombosis and early mortality. The patient’s plasma exhibited increased procoagulant activity and reduced responsiveness to activated protein C (APC). To define the mechanism, we generated recombinant FVIII-R571S and performed in vitro and in vivo studies. Consistent with the clinical phenotype, FVIII-R571S demonstrated a sixfold increase in 1-stage assay activity, whereas chromogenic substrate assay activity was comparable to wild-type FVIII (FVIII-WT). This discrepancy was explained by biochemical studies showing that activated FVIII-R571S (FVIIIa-R571S) has 10- to 20-fold higher affinity for activated factor IX (FIXa); notably, the chromogenic assay is insensitive to differences in FVIIIa-FIXa affinity. Additional analyses demonstrated that FVIII-R571S is inactivated by APC and protein S analogous to FVIII-WT, indicating that the variant is not intrinsically APC resistant. However, the increased affinity of FVIIIa-R571S for FIXa confers FIXa-dependent reduced A2-domain dissociation and APC-mediated inactivation in purified and plasma-based studies. These enhanced biochemical properties translated in vivo to a more potent procoagulant phenotype in hemophilia A mice. In the tail clip assay, FVIII-R571S exhibited a four- to fivefold increase in potency compared with FVIII-WT. In a thrombosis model, FVIII-R571S promoted significantly increased platelet and fibrin accumulation relative to FVIII-WT at equivalent antigen levels. Collectively, these data demonstrate that the prothrombotic phenotype of FVIII-R571S is driven by increased FIXa affinity, which enhances FVIIIa-FIXa complex assembly and function. The same mechanism confers reduced A2 dissociation and functional APC resistance, providing a unifying explanation for the observed gain-of-function phenotype.